TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03341481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femaltiker
Description: Patient had taken twice a day the product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient had taken twice a day the placebo
Study: NCT04085107

Intervention type: BEHAVIORAL
Intervention: Face-to-face interviews
Description: 243 PwMCI will receive two face-to-face interviews to complete two sets of questionnaires, of which 30 participants will be recruited attend a 1-hour semi-structured interview.
Study: NCT04505033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0017
Description: HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0017
Description: HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0017
Description: HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0017
Description: HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.
Study: NCT00316745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campto, Topotesin
Description: 100 mg/m2, IV (in the vein) on day 1,15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: S-1 Day1\~14, everyday P.O.(Day 15\~28 rest)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Plat
Description: Oxaliplatin (85mg/m2) Day 1, 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovorin
Description: l-leucovorin (200mg/m2) Day 1, 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1\~3 (48 hours) of each 28 day cycle.
Study: NCT04298164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START programme
Description: Acceptance and Commitment Therapy based programme for parents of children with Autism

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual in outpatient within outpatient psychology services
Study: NCT00386009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: 20 mg tadalafil tablet taken by mouth once a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken by mouth once a day for 12 weeks.
Study: NCT03318796

Intervention type: DEVICE
Group type: OTHER
Intervention: Coronary Artery Stenting
Description: Interventional coronary artery stent placement in De novo bifurcation lesions of the MB \& SB
Study: NCT00424203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT05261685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-step transepithelial PRK
Description: Single-step transepithelial Photorefractive keratectomy (PRK) is a corneal refractive surgical procedure utilized to correct myopia, hyperopia and astigmatism where excimer laser is used in a single step to remove the corneal epithelium followed by stromal laser ablation to correct the patient's refractive error.
Study: NCT02812849

Intervention type: DRUG
Intervention: Cu-64 DOTATATE

Intervention type: DRUG
Intervention: Cu-64 DOTATATE

Intervention type: DRUG
Intervention: Cu-64 DOTATATE
Study: NCT04334590

Intervention type: PROCEDURE
Intervention: Cleft Lip/Nose Repair without PSIO
Description: Standard of care surgical repair of cleft lip/nose without PSIO.

Intervention type: PROCEDURE
Intervention: Presurgical Infant Orthopedic Therapy
Description: Standard of care surgical repair of cleft lip/nose with PSIO.
Study: NCT03481205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ischemic conditioning device
Description: RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
Study: NCT03208543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HECT-CL
Description: To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
Study: NCT01492400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone Intravitreal Implant
Description: Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
Study: NCT00113347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 15 mg/m\^2 or 20 mg/m\^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
Study: NCT04343690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis management coaching
Description: Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic
Study: NCT02719249

Intervention type: OTHER
Intervention: Dried blood spot test
Study: NCT02707978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT03079271

Intervention type: DRUG
Group type: OTHER
Intervention: Lacrisert, 5 Mg Ophthalmic Insert
Study: NCT02173236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platform-switched implants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platform-matched implant
Study: NCT03716011

Intervention type: DEVICE
Group type: OTHER
Intervention: EXCROSSAL
Description: a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
Study: NCT01245322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactobacilli
Description: women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
Study: NCT02161848

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
Study: NCT01083277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: variable ventilation
Description: In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional ventilation
Description: tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
Study: NCT01936922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaitAid®
Description: Provides visual and auditory cues for walking.
Study: NCT02590185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocktail probe drugs
Description: For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~* A capsule of omeprazole ABBOTT® 10mg~* 10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~* 1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~* A tablet of fexofenadine Zentiva® 120mg
Study: NCT01962337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA008
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA008
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA008
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion
Study: NCT01358565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fx-1006A
Description: A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fx-1006A
Description: A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
Study: NCT03358849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cell
Description: Patients who received natural killer cell injection
Study: NCT05614570

Intervention type: DEVICE
Intervention: SSVEP Device
Description: Non-invasive, non-interventional SSVEP sensor device

Intervention type: DEVICE
Intervention: SSVEP Device
Description: Non-invasive, non-interventional SSVEP sensor device

Intervention type: OTHER
Intervention: SCAT5
Description: The Sport Concussion Assessment Tool version 5

Intervention type: OTHER
Intervention: SCAT5
Description: The Sport Concussion Assessment Tool version 5
Study: NCT04172649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupressure
Description: On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
Study: NCT01722877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JetStream Navitus
Description: Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
Study: NCT03494322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg given IV

Intervention type: DRUG
Group type: OTHER
Intervention: Avelumab
Description: Avelumab 10 mg/kg given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500\* mg/m2 given IV~\*Cetuximab dose will be dependent on outcome of safety run-in.
Study: NCT01079988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins
Description: Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoids
Description: Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Description: Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids/methotrexate
Description: Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
Study: NCT05273866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual Reality video application reduces pain by distracting. The intervention group was watched video during the procedure, starting before the procedure.
Study: NCT01293422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 600 mg daily for a week
Study: NCT02781727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once weekly subcutaneous injection of TransCon hGH
Description: Once weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once daily subcutaneous injection of Genotropin
Description: Once daily subcutaneous injection
Study: NCT04341285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECMO Implantation
Description: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECMO Implantation
Description: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
Study: NCT01976286

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salicylic Acid Peels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glycolic Acid Peels
Study: NCT01128686

Intervention type: OTHER
Intervention: No intervention
Description: This study is retrospective chart review
Study: NCT05465239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurePace Powered Walker User
Description: Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
Study: NCT00584298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMS995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00832377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: timolol/dorzolamide combination
Description: Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
Study: NCT03328260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: Transvaginal high intensity focused ultrasound to ablate uterine myoma
Study: NCT04457999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipiflow Thermal pulsation
Description: Single vectored thermal pulsation treatment for dry eye
Study: NCT03463278

Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy Rate
Description: The pregnancy and live birth rate according to number of blastocysts formed in our three groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy Rate
Description: The pregnancy and live birth rate according to number of blastocysts formed in our three groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy Rate
Description: The pregnancy and live birth rate according to number of blastocysts formed in our three groups
Study: NCT02873910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AS-119

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01051505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
Study: NCT01837862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients \< 12kg: 0.05 mg/kg; for patient \> 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
Study: NCT01697878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP followed by atmospheric pressure
Description: In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atmospheric pressure followed by CPAP
Description: In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
Study: NCT02460159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZ 10 mg/Atorva 20 mg FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZ 10 mg/Atorva 10 mg FDC
Study: NCT00969566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin, metformin
Description: sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
Study: NCT03727100

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Micropellets
Description: Injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Injection